10x Genomics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 6, 2026, reporting condensed consolidated balance sheet figures and share counts as of that date.

Key Highlights

  • Cash and cash equivalents: $526,187 thousand as of September 30, 2026, up from $473,966 thousand as of December 31, 2025, according to the filing.
  • Total assets: $1,063,129 thousand as of September 30, 2026, compared to $1,041,365 thousand as of December 31, 2025, the company disclosed.
  • Shares outstanding: As of October 30, 2026, the registrant reported 121,455,317 shares of Class A common stock and 10,078,872 shares of Class B common stock outstanding.
  • Marketable securities: $49,493 thousand as of September 30, 2026, versus $49,443 thousand at year-end 2025, per the filing.
  • Total current liabilities: $140,370 thousand as of September 30, 2026, down from $153,454 thousand as of December 31, 2025, according to the filing.
  • Goodwill: $6,918 thousand as of September 30, 2026, increased from $4,511 thousand as of December 31, 2025, the company reported.

10x Genomics Balance Sheet Position for the Quarter Ended September 30, 2026

According to the Form 10-Q filed on NASDAQ:TXG, 10x Genomics, Inc. reported total assets of $1,063,129 thousand as of September 30, 2026, an increase from $1,041,365 thousand as of December 31, 2025. The company disclosed cash and cash equivalents of $526,187 thousand at the end of the third quarter, up from $473,966 thousand at the prior year-end. Marketable securities stood at $49,493 thousand, and accounts receivable, net, were $55,701 thousand, compared to $47,013 thousand at December 31, 2025.

On the liabilities side, the filing reported total current liabilities of $140,370 thousand as of September 30, 2026, a decrease from $153,454 thousand at December 31, 2025. Accounts payable rose to $21,594 thousand from $12,733 thousand at year-end 2025. Contingent consideration classified as current stood at $12,036 thousand, down from $23,363 thousand at December 31, 2025. Deferred revenue was $22,956 thousand, compared to $23,902 thousand at December 31, 2025. The filing also noted that inventory increased to $64,629 thousand from $56,341 thousand over the same period.

The filing stated that as of October 30, 2026, the registrant had 121,455,317 shares of Class A common stock and 10,078,872 shares of Class B common stock outstanding, each with a par value of $0.00001 per share. The company disclosed that it is a large accelerated filer. The filing also referenced acquisitions of Scale Biosciences, Inc. and Proteintech Genomics, Inc. in its forward-looking statements section. The forward-looking statements contained in the filing are the company's own and are subject to its stated cautionary language.

What Was Disclosed

10x Genomics filed a quarterly report covering the period ended September 30, 2026, disclosing condensed consolidated balance sheet data, share counts as of October 30, 2026, and other financial statement items for the third quarter of fiscal 2026.